2016-04 HCV – Guidelines for the screening, care and treatment – Updated WHO
Globally, the morbidity and mortality attributable to hepatitis C virus (HCV) infection continues to increase. Approximately 700 000 persons die each year from HCVrelated complications, which include cirrhosis, hepatocellular carcinoma (HCC) and liver failure. HCV infection can be cured by antiviral treatment; however, due to the asymptomatic nature of the disease, many infected persons are unaware of their infection and, for those who are diagnosed, access to treatment remains poor in many settings.
The field of HCV therapeutics continues to evolve rapidly and, since the World Health Organization (WHO) issued its first Guidelines for the screening, care and treatment of persons with hepatitis C infection in 2014, several new medicines have been approved by at least one stringent regulatory authority. These medicines, called direct-acting antivirals (DAAs), are transforming the treatment of HCV, enabling regimens that can be administered orally, are of shorter duration (as short as eight weeks), result in cure rates higher than 90%, and are associated with fewer serious adverse events than the previous interferoncontaining regimens. WHO is updating its hepatitis C treatment guidelines to provide recommendations for the use of these new medicines….
Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection – MARCH 2015 Outbreak of hand, foot, and mouth disease caused by coxsackievirus A6 among basic military trainees — Texas, 2015.